慢性创伤性脑病神经病理改变的临床与神经心理学特征:匹配病例系列研究
CTE-NC仅占0.8%(29/3,845),匹配后比较25例CTE-NC与97例无CTE-NC者;两组神经心理学评分、神经精神症状及帕金森症状无差异,但CTE-NC组海马硬化、其他tau蛋白病及TDP-43包涵体比例更高,创伤性脑损伤史比例也更高。
要点
- CTE-NC在NACC数据库中罕见,仅占0.8%(29/3,845)。
- CTE-NC组海马硬化、其他tau蛋白病及TDP-43包涵体比例显著高于对照组。
- 两组神经心理学评分、神经精神症状及帕金森症状未见差异。
核心结论
- CTE-NC在NACC数据库中罕见,有CTE-NC者临床症状与无CTE-NC者无差异,但海马硬化、其他tau蛋白病及TDP-43包涵体比例更高。
研究设计与样本
- CTE-NC者按人口学(年龄、教育、性别)及阿尔茨海默与路易体神经病理分期约1:4匹配无CTE-NC者。
- 最终比较样本为25例CTE-NC与97例无CTE-NC者,采用卡方检验与协方差分析(协变量为认知症状持续时间、至死亡时间及认知诊断)。
主要发现
- CTE-NC自2014年以来占参与者的0.8%(29/3,845)。
- CTE-NC组除1人外均为男性,平均年龄74.7岁(SD=8.0)。
- CTE-NC组中重度阿尔茨海默神经病理常见(54.0%),皮质或边缘型路易体包涵体较少(8.0%)。
- CTE-NC组创伤性脑损伤史比例为45.8%,高于无CTE-NC组的21.9%(p=0.018,V=0.217)。
- 两组神经心理学评分、神经精神症状及帕金森症状无差异。
关键数值与推荐
- 海马硬化:CTE-NC组40.0% vs 无CTE-NC组9.6%(p<0.001,V=0.338)。
- 进行性核上性麻痹:16.0% vs 3.1%(p=0.013,V=0.224)。
- 其他4R tau蛋白病:16.7% vs 3.1%(p=0.011,V=0.231);其他3R+4R tau蛋白病:8.3% vs 1.0%(p=0.039,V=0.187)。
- 衰老相关tau星形胶质细胞病:33.0% vs 8.9%(p<0.001,V=0.313);TDP-43包涵体:24.0% vs 7.0%(p=0.017,V=0.228)。
临床怎么用
- 对存在创伤性脑损伤史者,即便神经心理学与运动症状不突出,也应关注CTE-NC相关共病病理的可能。
- CTE-NC患者临床可无特异性症状,诊断需依赖神经病理评估,临床不宜仅凭症状推断CTE-NC。
局限性
- NACC缺乏CTE-NC严重程度与分布数据,也无法进行重复性头部撞击数据的敏感性分析。
- CTE-NC病例数少(25例),且几乎均为男性,样本代表性有限。
- 亟需更大规模的活体临床-病理研究以关联CTE-NC与临床特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: This retrospective study used data from the National Alzheimer's Coordinating Center (NACC) database and compared neuropathologic, neuropsychiatric, motor, and neuropsychological features between those with and without chronic traumatic encephalopathy neuropathologic change (CTE-NC). METHODS: Data were obtained from the NACC database from 2014 to December 2024, with the only inclusion criterion being evaluation for CTE-NC. Participants with CTE-NC were identified and matched approximately 1:4 to those without CTE-NC on demographics (age, education, sex) and staging of Alzheimer and Lewy body neuropathology. Chi-square tests and analyses of covariance (covarying for cognitive symptom duration, time to death, and cognitive diagnosis) compared neuropathologic features, history of traumatic brain injury (TBI), neuropsychiatric symptoms, parkinsonism features, and neuropsychological scores between groups. RESULTS: CTE-NC was present in 0.8% of participants (29/3,845) since 2014. Matching on a 1:4 ratio was achieved for 22 individuals and 1:3 for an additional 3, yielding a total comparison sample of 25 with CTE-NC and 97 without. All but 1 individual with CTE-NC were male with a mean age of 74.7 years (SD = 8.0). Moderate-to-severe Alzheimer neuropathology (54.0%) was common in those with CTE-NC while comorbid cortical or limbic Lewy inclusions were less frequent (8.0%). Compared with those without CTE-NC, those with CTE-NC had higher rates of hippocampal sclerosis (40.0% vs 9.6%; p < 0.001, V = 0.338), progressive supranuclear palsy (16.0% vs 3.1%; p = 0.013, V = 0.224), argyrophilic grain disease (28.0% vs 10,3%; p = 0.023, V = 0.206), other 4R tauopathies (16.7% vs 3.1%; p = 0.011, V = 0.231), other 3R + 4R tauopathies (8.3% vs 1.0%; p = 0.039, V = 0.187), aging-related tau astrogliopathy (33.0% vs 8.9%; p < 0.001, V = 0.313), and transactive response DNA binding protein 43 (TDP-43) inclusions (24.0% vs 7.0%; p = 0.017, V = 0.228). Those with CTE-NC had higher rates of TBI (45.8%) compared with those without CTE-NC (21.9%, p = 0.018, V = 0.217). Neuropsychological scores, neuropsychiatric symptoms, and parkinsonism symptoms did not differ between groups. DISCUSSION: CTE-NC was rare in NACC since 2014. Those with CTE-NC did not differ in clinical symptoms but had higher rates of hippocampal sclerosis, other tauopathies, and TDP-43 inclusions. In this clinicopathologic investigation using in vivo clinical data, although NACC lacks CTE-NC severity/distribution and repetitive head impact data for sensitivity analyses. Larger in vivo clinicopathologic studies are greatly needed to correlate CTE-NC with clinical features.
引用
- Schaffert J, Iyengar N, Magill R, et al. Clinical and Neuropsychological Profiles in People With Chronic Traumatic Encephalopathy Neuropathologic Change: Matched Case-Series Study. Neurology. 2025. PMID: 40882174. doi:10.1212/WNL.0000000000214012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。